Division of Cardiology, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Naples, Italy.
Eur Rev Med Pharmacol Sci. 2020 Sep;24(17):9169-9171. doi: 10.26355/eurrev_202009_22867.
NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome has recently become an intriguing target of several chronic and viral diseases. Here, we argue that targeting NLRP3 inflammasome could be a strategy to prevent cardiovascular outcomes [fulminant myocarditis, heart failure, venous thromboembolism (VTE)] and acute respiratory distress syndrome (ARDS) in patients with SARS-CoV-2 infection. We discuss the rationale for NLRP3 targeting in clinical trials as an effective therapeutic strategy aimed to improve prognosis of COVID-19, analyzing the potential of two therapeutic options (tranilast and OLT1177) currently available in clinical practice.
NLRP3（核苷酸结合寡聚化结构域样受体热蛋白结构域 3）炎性小体最近成为几种慢性和病毒性疾病的一个研究热点。在这里，我们认为靶向 NLRP3 炎性小体可能是预防 SARS-CoV-2 感染患者心血管结局（暴发性心肌炎、心力衰竭、静脉血栓栓塞症[VTE]）和急性呼吸窘迫综合征（ARDS）的一种策略。我们讨论了 NLRP3 靶向治疗在临床试验中的合理性，作为一种旨在改善 COVID-19 预后的有效治疗策略，并分析了目前临床可用的两种治疗选择（曲尼司特和 OLT1177）的潜力。
